ꟷ Clinerion has been certified by EHDEN (European Health Data & Evidence Network) to map health data from various formats to the OMOP common data model.
ꟷ As an OMOP ambassador, Clinerion will support the speeding up of the process to map health data from various formats and institutions to the OMOP common data model in Europe.
Clinerion was selected as one of eleven SMEs (Small and medium-sized enterprises) from a pool of twenty-eight eligible applications to the first EHDEN pilot call this year, to be trained and certified, with the objective to speed up the process to map health data from various formats and institutions to the OMOP common data model.
EHDEN aims to develop a federated and equitable ecosystem of institutions generating clinical data, with researchers across academia and industry, supported by certified and qualified SMEs, harmonizing clinical data and creating a network technology for real-world research. It will incorporate appropriate policy and regulatory requirements, such as the General Data Protection Regulation (GDPR) and ethical research guidelines, via privacy by design in its sociotechnical infrastructure.
Central to EHDEN will be the standardization of health data to the ‘Observational Medical Outcomes Partnership’ (OMOP) common data model (CDM) and the utilization of analytical tools such as those developed by the international ‘Observational Health Data Sciences and Informatics’ (OHDSI) open science collaboration and others.
EHDEN aims to harmonize 100 million anonymised health records over five years across multiple hospitals, primary care networks, regional databases, and similar, while developing a durable and sustainable network of mutual research interests. During the project, numerous use cases will validate EHDEN’s work with a focus on health outcomes, measured by relevant health outcome standards.
“We warmly welcome this initial group of SMEs, says Associate Prof. Peter Rijnbeek, Erasmus Medical Center, Rotterdam, The Netherlands and Coordinator of EHDEN. “EHDEN provides SMEs with free training and certification, an ability to expand their market presence and work with our Data Partners, and to be part of a transformational initiative that will have positive impact on patient outcomes across Europe through open science.”
“Establishing this SME network throughout Europe is a critical step in building an eco-system that supports a range of Data Partners and other stakeholders in mapping and using health data,” says Nigel Hughes, Janssen Scientific Director RWD/WRE, and Co-Lead of EHDEN. “Certified, these SMEs, together with the Data Partners that will be joining in the coming months and years, become a key part of the EHDEN community,” he added.
“Clinerion is proud to be certified by EHDEN in its efforts to tap into the potential of real-world data,” says Ian Rentsch, CEO of Clinerion. “In our support of the improvement of patient treatments and outcomes, we are dedicated to rendering patient data worldwide mutually intelligible and the OMOP data model is fully interoperable with Clinerion’s Patient Network Explorer. We look forward to working closely with EHDEN and OHDSI on tapping into the transformational potential of real-world data.”
Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
Clinerion website: www.clinerion.com
Clinerion’s Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer
For more information, please contact:
Le Vin Chin
Director, Head of Marketing & Communications
Elisabethenanlage 11, 4051 Basel, Switzerland
Tel.: +41 61 865 60 54
About EHDEN (European Health Data & Evidence Network)
Every day, patients are suffering or dying because we are not able to tap into the unlimited potential of real-world data. In response to this, the European Health Data and Evidence Network, was created as a public-private partnership under the framework of the Innovative Medicines Initiative.
The EHDEN project was launched as a public-private partnership under the framework of IMI2 (Innovative Medicines Initiative), with eleven public partners, led by Erasmus Medical Centre, Rotterdam NL, and eleven pharmaceutical partners, led by Janssen Pharmaceutica, Belgium, working together as a consortium. EHDEN is disease-agnostic and aspires to provide a new paradigm for the discovery and analysis of health data in Europe.
EHDEN aspires to enable transparent and reproducible research using real-world data at an unprecedented scale. This will allow better regulatory decision-making, better outcomes, and ultimately better care for patients across Europe. To achieve this, EHDEN is creating a large-scale, federated network of harmonised data sources standardised to the OMOP common data model.
EHDEN website: www.ehden.eu
OHDSI website: www.ohdsi.org
EHDEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
For more information, please contact: